Log In
BCIQ
Print this Print this
 

Rifaximin DR

  Manage Alerts
Collapse Summary General Information
Company Valeant Pharmaceuticals International Inc.
DescriptionRifaximin delayed release formulation
Molecular Target Bacterial RNA polymerase (RNAP)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationCrohn's disease
Indication DetailsTreat Crohn's disease
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$12,524.0M

$11,689.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/01/2015

$11,400.0M

$11,400.0M

0

03/11/2015

$1,124.0M

$289.0M

0

Get a free BioCentury trial today